Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus.
Mycophenolate mofetil (MMF) has been increasingly used in patients with systemic lupus erythematosus (SLE). While most information concentrates on lupus nephritis, its efficacy in nonrenal manifestations of SLE has not been systematically studied. We describe the successful use of MMF in a patient with SLE-related hemolytic anemia that was refractory to cyclophosphamide, pulse methylprednisolone, intravenous immunoglobulin and cyclosporine. The mechanisms of action of MMF are briefly reviewed.
Mak
A
A
Department of Medicine, Tuen Mun Hospital, New Territories, Hong Kong SAR, China. anselmmak@netvigator.com
Mok
C C
CC
D000328:Adult; D000743:Anemia, Hemolytic / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000753:Anemia, Refractory / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid